Last reviewed · How we verify
LY900003
LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss.
LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | LY900003 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
LY900003 binds to and activates the GLP-1 receptor, which enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signals to the brain. This multi-modal action reduces blood glucose levels and decreases appetite, making it suitable for treating type 2 diabetes and obesity.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer (PHASE2)
- Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer (PHASE3)
- ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma (PHASE2)
- A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer (PHASE3)
- A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY900003 CI brief — competitive landscape report
- LY900003 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI